It is therefore imperative to dissect the expression patterns of BCL2 in ETP-ALL, as this is not only crucial for prognostic stratification but also for identifying patients who may benefit from targeted therapies, such as venetoclax, which directly inhibit BCL2-dependent survival mechanisms [9]. This evidence concerns the gene BCL2 and acute lymphoblastic leukemia.